Iloperidone

證據等級: L5

預測適應症: 10 個

Iloperidone: From Schizophrenia to Bipolar Mania

One-Sentence Summary

Iloperidone (Fanapt) is a D2/5-HT2A dual antagonist originally developed and marketed for the treatment of schizophrenia. The TxGNN model's most credible signal among its top predictions points to manic episodes of Bipolar I Disorder, an indication that is supported by 1 completed Phase 4 trial, 1 completed Phase 3 RCT, and 19 related publications, including confirmation that this indication received formal regulatory approval in 2024. Nine other very high-scoring TxGNN predictions for this drug are also reported, but none of them have any corroborating clinical trial or literature evidence and are assessed as likely false positives.

Quick Overview

Item	Content
Original Indication	Schizophrenia (per literature evidence, e.g. PMID 22849428, 21446639)
Predicted New Indication	Manic Bipolar Affective Disorder
TxGNN Prediction Score	99.98%
Evidence Level	L1
Market Status	✗ Not marketed (0 authorizations on file)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Iloperidone is a serotonin/dopamine antagonist (5-HT2A/D2), the same pharmacological class as several atypical antipsychotics already approved for bipolar mania — olanzapine, risperidone, quetiapine, aripiprazole, asenapine, and cariprazine. This shared receptor-binding profile gives strong mechanistic plausibility for extending iloperidone's use from schizophrenia to acute manic/mixed episodes of Bipolar I Disorder.

This is not purely a model-generated hypothesis: PMID 39008105 (The Medical Letter, 2024) documents that iloperidone received a new FDA-approved indication for bipolar disorder in 2024, and PMID 38236020 reports the pivotal Phase 3, randomized, double-blind, placebo-controlled trial (27 sites, US and international, 2021–2022) that demonstrated significant reduction in Young Mania Rating Scale (YMRS) scores versus placebo. A completed Phase 4 trial (NCT02413918) further examined iloperidone as adjunctive therapy in mixed-state bipolar disorder. Taken together, the TxGNN prediction here aligns with real-world regulatory and clinical outcomes rather than an unvalidated model artifact.

Other TxGNN High-Score Predictions Without Supporting Evidence

The evidence pack also contains nine other candidate indications with near-identical, extremely high TxGNN scores (~99.999%, ranks 24–39): retinal dystrophy, congenital disorder of glycosylation with defective fucosylation, hydranencephaly, Charcot-Marie-Tooth disease type 1G, perisylvian polymicrogyria syndrome, three forms of syndromic/hereditary myopia, and atypical glycine encephalopathy. None of these have any associated clinical trials, and where literature was retrieved (retinal dystrophy), the papers are unrelated general ophthalmology/genetics topics with no mention of iloperidone or antipsychotic mechanisms. These are judged to be likely false positives arising from knowledge-graph embedding similarity rather than genuine biological association, and all carry a "Hold" recommendation. They are not developed further in this report.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02413918	Phase 4	Completed	41	Open-label study of iloperidone as adjunctive treatment (with lithium, divalproex, and/or lamotrigine) in mixed states of bipolar disorder; assessed acute and long-term bimodal efficacy and predictors of treatment response.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38236020	2024	RCT (Phase 3)	J Clin Psychiatry	Randomized, double-blind, placebo-controlled trial (27 sites); iloperidone up to 24 mg/day significantly reduced YMRS scores at 4 weeks vs. placebo in adults with bipolar mania.
39008105	2024	Regulatory Update	The Medical Letter	Reports FDA approval of a new bipolar disorder indication for iloperidone (Fanapt).
39800949	2025	Review	Ann Pharmacother	Evaluates efficacy of iloperidone for bipolar I mania and discusses safety profile (QTc prolongation, orthostatic hypotension, metabolic effects).
28817490	2017	Open-label Trial	J Clin Psychopharmacol	Open trial of iloperidone in mixed episodes of bipolar disorder; notes difficulty of treating mixed states and gaps in depression-response reporting for FDA-approved agents.
22900950	2012	Systematic Review/Meta-analysis	CNS Drugs	Compares body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in schizophrenia and bipolar disorder.
33177350	2021	Comparative Study	J Clin Psychopharmacol	Compares metabolic characteristics of newer second-generation antipsychotics (including iloperidone) against olanzapine.
41826282	2026	Pharmacogenomic Analysis	Pharmacogenomics J	Secondary analysis of the Phase 3 bipolar mania trial; SLC2A9 variant associated with iloperidone-related uric acid increase.
39126643	2024	Review (Safety/QTc)	Expert Opin Drug Saf	Updated safety review of atypical antipsychotics and QTc/Torsades de Pointes risk, relevant to iloperidone's known cardiac signal.
22849428	2012	Review	Expert Opin Pharmacother	Primer on iloperidone, asenapine, and lurasidone; confirms iloperidone's original schizophrenia indication and shared receptor mechanism relevant to bipolar disorder.
18095919	2008	Review	Expert Opin Investig Drugs	Early profile of iloperidone as a 5-HT2A/D2 antagonist under development for schizophrenia and bipolar disorder.

Market Information

The drug is currently not marketed and holds no marketing authorizations on file (0 licenses recorded). No dosage form or approved-indication data are available for local review.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted bipolar mania indication is supported by a completed Phase 3 RCT, a completed Phase 4 trial, and confirmed 2024 regulatory approval in at least one market, giving it L1-level evidence — substantially stronger than iloperidone's other nine TxGNN predictions, which lack any clinical or mechanistic support and should be held. However, the complete absence of local marketing authorization, package-insert warnings/contraindications, and MOA documentation (both flagged as Blocking/High severity data gaps) means the candidate cannot yet clear initial safety screening (S1).

To proceed, the following is needed:

Obtain the official package insert (warnings, contraindications, DDI) from the relevant regulatory authority to close data gap DG001 (Blocking)
Retrieve formal mechanism-of-action documentation from DrugBank to close data gap DG002 (High)
Confirm local marketing authorization status and pathway if repurposing submission is pursued
Monitor known class-wide risks identified in the literature (QTc prolongation, orthostatic hypotension, metabolic/weight effects, akathisia) as part of any safety monitoring plan
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.